Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.65 |
| ▸ | KIF11 | P52732 | 3/20 | 0.65 |
| ▸ | PKM | P14618 | 3/20 | 0.46 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.44 |
| ▸ | MMP12 | P39900 | 1/20 | 0.43 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | IDH1 | O75874 | 1/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24864966 | 1.00 | TRPV1 (0.65) | TRPV1KIF11PKMGABRG2GABRB3 | |
| SCHEMBL762348 | 0.84 | TRPV1 (0.58) | TRPV1KIF11PKMMMP12POLB | |
| SCHEMBL6297431 | 0.82 | KIF11 (0.62) | TRPV1KIF11PKMGABRG2GABRB3 | |
| SCHEMBL6297491 | 0.82 | KIF11 (0.58) | TRPV1KIF11PKMPOLB | |
| SCHEMBL10269414 | 0.81 | KIF11 (0.60) | TRPV1KIF11PKMGABRG2GABRB3 | |
| SCHEMBL13675531 | 0.80 | TRPV1 (1.00) | TRPV1POLB | |
| SCHEMBL13676060 | 0.79 | TRPV1 (0.66) | TRPV1KIF11POLB | |
| SCHEMBL12362001 | 0.79 | KIF11 (0.56) | TRPV1KIF11PKMGABRG2GABRB3 | |
| SCHEMBL16208445 | 0.79 | KIF11 (1.00) | TRPV1KIF11PKMPOLB | |
| SCHEMBL23432581 | 0.76 | KIF11 (0.54) | TRPV1KIF11PKMGABRG2GABRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327393-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2024-10-03 | — | — | US | disclosed |
| CN-117999259-A | Iron death modulators, their preparation and use | 维泰瑞隆有限公司 | 2024-05-07 | — | — | CN | disclosed |
| WO-2023280296-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2023-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327393-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | AIFM2, GPX1, GPX4 | TRPV1 3135/4885KIF11 4664/4885PKM 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.